Search

Drug Profiles Catalysts Company Profiles Impact Events Target
Indication Trials KOL Insight Special Reports All

Drug Impact Events

Date Lead
Company
Event Type Approval
Change
Approval
Likelihood
11/26/14 Bristol-Myers Squibb (BMY) Daclatasvir for Hepatitis C (HCV) (Antiviral) Subscribers Only Subscribers Only Subscribers Only
11/25/14 Amgen (AMGN) Brodalumab for Psoriasis Subscribers Only Subscribers Only Subscribers Only
11/25/14 Novartis (NVS) Farydak for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
11/24/14 Prosensa Holding (RNA) Drisapersen for Muscular Dystrophy Subscribers Only Subscribers Only Subscribers Only
11/24/14 Juno Therapeutics JCAR015 for Acute Lymphocytic Leukemia (ALL) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

Expected
Date Range
Lead
Company
Drug Expected
Catalyst
11/26/14 Subscribers Only Subscribers Only Regulatory - PDUFA/Approval Decision (US)
Now - 12/01/14 Subscribers Only Subscribers Only Regulatory - Approval Decision (Europe)
Now - 12/01/14 Subscribers Only Subscribers Only Regulatory - Approval Decision (Europe)
Now - 12/01/14 Subscribers Only Subscribers Only Regulatory - Approval Decision (Europe)
12/01/14 Subscribers Only Subscribers Only Patent - Expiration